Pipeline

TriSalus is focused on improving the response rates in tumors of the liver and pancreas by studying an innovative platform that integrates immunomodulation therapy with proprietary intravascular regional delivery. The goal of this approach is to help overcome the substantial challenges associated with treating liver and pancreatic tumors with immunotherapy.

The safety and efficacy of these products have not been established by health authorities. These products are investigational and have not been approved in the US or globally.

Primary Pancreatic Cancers

Nelitolimod (also known as SD-101) via PEDD™ PVRI™ + systemic checkpoint inhibitors.

IND-enabling
phase
Phase 1
phase
Phase 2
phase
Phase 3
phase

Primary Liver Cancers

Nelitolimod via PEDD™ + systemic checkpoint inhibitors.
Learn more at clinicaltrials.gov

IND-enabling
phase
Phase 1
phase
Phase 2
phase
Phase 3
phase

Nelitolimod via PEDD™ + systemic checkpoint inhibitors.
Learn more at clinicaltrials.gov

IND-enabling
phase
Phase 1
phase
Phase 2
phase
Phase 3
phase
*HCC and ICC will be studies in single phase 1b study (separate cohorts in phase 2)

Liver Metastases

Nelitolimod via PEDD™ + systemic checkpoint inhibitors.
Learn more at clinicaltrials.gov

IND-enabling
phase
Phase 1
phase
Phase 2
phase
Phase 3
phase

Nelitolimod via PEDD™ + systemic checkpoint inhibitors.

IND-enabling
phase
Phase 1
phase
Phase 2
phase
Phase 3
phase

Nelitolimod via PEDD™ + systemic checkpoint inhibitors.

IND-enabling
phase
Phase 1
phase
Phase 2
phase
Phase 3
phase

Therapeutic Candidates

Candidate nelitolimod

We believe our investigational immunotherapeutic, nelitolimod has the potential to re-activate the immune system within the liver and pancreas and enable deeper and more durable responses to other immunotherapeutics, such as checkpoint inhibitors, resulting in better patient outcomes.

Nelitolimod is in clinical development and has not been approved in the US or globally.

Nelitolimod
Scientific illustration of TriSalus’ investigational candidate SD-101, a single stranded oligonucleotide-based therapy

Therapeutic Candidates

Scientific illustration of TriSalus’ investigational candidate SD-101, a single stranded oligonucleotide-based therapy

Candidate SD-101

We believe our investigational immunotherapeutic, SD-101 has the potential to re-activate the immune system within the liver and pancreas and enable deeper and more durable responses to other immunotherapeutics, such as checkpoint inhibitors, resulting in better patient outcomes.

SD-101 is in clinical development and has not been approved in the US or globally.

SD-101

Partners

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

CANCEL